How CRISPR stacks up against more established new modalities
A side-by-side analysis of the risks and benefits of new genetic modalities
The first indication that CRISPR-based gene editing can work when injected systemically brings competition from the emerging technology closer to reality for creators of RNAi and antisense therapies, but time will tell whether one modality emerges as dominant or each eventually carves its own space on the market.
CRISPR-Cas9, RNAi and antisense oligonucleotides all regulate protein expression by acting at the genetic level. They also all naturally target the liver when injected systemically, and are effective at knocking down genes. ...